{"nctId":"NCT01099449","briefTitle":"Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy","startDateStruct":{"date":"2010-06"},"conditions":["Chemotherapeutic Agent Toxicity","Colorectal Cancer","Neuropathy","Neurotoxicity"],"count":362,"armGroups":[{"label":"Arm I","type":"EXPERIMENTAL","interventionNames":["Drug: calcium gluconate","Drug: magnesium sulfate","Drug: oxaliplatin"]},{"label":"Arm II","type":"PLACEBO_COMPARATOR","interventionNames":["Other: placebo","Drug: oxaliplatin"]},{"label":"Arm III","type":"EXPERIMENTAL","interventionNames":["Drug: calcium gluconate","Drug: magnesium sulfate","Other: placebo","Drug: oxaliplatin"]}],"interventions":[{"name":"calcium gluconate","otherNames":[]},{"name":"magnesium sulfate","otherNames":[]},{"name":"placebo","otherNames":[]},{"name":"oxaliplatin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"DISEASE CHARACTERISTICS:\n\n* Histologically confirmed adenocarcinoma of the colon or rectum\n* Has undergone curative resection and is considered to have stage II or III disease or completely resected stage IV disease with no evidence of residual tumor\n* Scheduled to receive 6 months of oxaliplatin-based adjuvant chemotherapy with 85 mg/m\\^2 oxaliplatin every 2 weeks (this includes, for instance, FOLFOX4 or modified FOLFOX6)\n\n  * Patients receiving bevacizumab or cetuximab in combination with FOLFOX as part of a clinical trial or clinical practice are eligible\n\nPATIENT CHARACTERISTICS:\n\n* ECOG performance status 0-2\n* WBC ≥ 3,000/mm\\^3\n* ANC ≥ 1,500/mm\\^3\n* Platelet count ≥ 100,000/mm\\^3\n* Hemoglobin ≥ 10.0 g/dL\n* Total bilirubin ≤ 1.5 times upper limit of normal (ULN)\n* Serum creatinine ≤ 1.5 times ULN\n* Serum calcium ≤ 1.2 times ULN\n* Serum magnesium ≤ 1.2 times ULN\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* Able to complete questionnaires (alone or with assistance)\n* Able to comply with study treatment\n* Willing to return to enrolling institution for follow-up\n* Willing to provide blood sample for research purposes\n* No pre-existing peripheral neuropathy of any grade\n* No family history of a genetic/familial neuropathy\n* No second or third degree AV heart block or a history of second or third degree heart block\n\n  * Bundle branch blocks are allowed.\n* No other medical conditions that, in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* Central venous access line present, or scheduled to have a central line placed before starting chemotherapy and study treatment\n* No prior treatment with neurotoxic chemotherapy (e.g., oxaliplatin, cisplatin, taxanes, or vinca alkaloids)\n* No concurrent digitalis medication\n* No concurrent treatment with the anticonvulsants carbamazepine (e.g., Tegretol®), phenytoin (e.g., Dilantin®), valproic acid (e.g., Depakene®), gabapentin (Neurontin®), or pregabalin (Lyrica®)\n* No concurrent neurotropic agents, including venlafaxine (Effexor), desvenlafaxine (Pristiq®), milnacipran (Savella®), or duloxetine (Cymbalta)\n* No concurrent tricyclic antidepressants (such as amitryptilline), or any other agent specifically being given to prevent or treat neuropathy\n* No concurrent drugs given as a neuroprotectant","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Sensory Area Under the Curve(AUC) Score. Oxaliplatin-induced Sensory Neuropathy as Repeatedly Measured by the EORTC QLQ-CIPN20 Sensory Subscale During Chemotherapy","description":"The oxaliplatin-induced sensory neuropathy as repeatedly measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire of Chemotherapy-induced peripheral neuropathy (EORTC QLQ-CIPN20) sensory subscale during the chemotherapy. This is a multivariate repeated measurement of CIPN with possibly variable cycles for every patient. The CIPN sensory subscale will be calculated by standard scoring algorithm and converted to 0-100 scale, where higher scores represent a higher quality of life. Rather than choosing the CIPN20 sensory subscale at a fixed cycle of chemotherapy, we will adopt a summary measure, area under the curve (AUC) of CIPN20 sensory subscale as the primary endpoint. This AUC will be prorated by the number of chemotherapy cycles patients received.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89.2","spread":"8.5"},{"groupId":"OG001","value":"88.3","spread":"9.7"},{"groupId":"OG002","value":"87.1","spread":"9.9"}]}]}]},{"type":"SECONDARY","title":"Area Under the Curve (AUC) of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire of Chemotherapy-induced Peripheral Neuropathy (EORTC QLQ-CIPN20) Autonomic Neuropathy Subscale Scores","description":"The oxaliplatin-induced autonomic neuropathy as repeatedly measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire of Chemotherapy-induced peripheral neuropathy (EORTC QLQ-CIPN20) autonomic subscale during the chemotherapy. This is a multivariate repeated measurement of CIPN with possibly variable cycles for every patient. The CIPN autonomic subscale will be calculated by standard scoring algorithm and converted to 0-100 scale, where higher scores represent a higher quality of life. Rather than choosing the CIPN20 autonomic subscale at a fixed cycle of chemotherapy, we will adopt a summary measure, area under the curve (AUC) of CIPN20 autonomic subscale as the endpoint. This AUC will be prorated by the number of chemotherapy cycles patients received.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89.8","spread":"12.5"},{"groupId":"OG001","value":"86.7","spread":"14.3"},{"groupId":"OG002","value":"84.5","spread":"15.1"}]}]}]},{"type":"SECONDARY","title":"Area Under the Curve (AUC) of European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire of Chemotherapy-induced Peripheral Neuropathy (EORTC QLQ-CIPN20) Motor Neuropathy Subscale Scores","description":"The oxaliplatin-induced motor neuropathy as repeatedly measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire of Chemotherapy-induced peripheral neuropathy (EORTC QLQ-CIPN20) motor neuropathy subscale during the chemotherapy. This is a multivariate repeated measurement of CIPN with possibly variable cycles for every patient. The CIPN motor neuropathy subscale will be calculated by standard scoring algorithm and converted to 0-100 scale, where higher scores represent a higher quality of life. Rather than choosing the CIPN20 motor neuropathy subscale at a fixed cycle of chemotherapy, we will adopt a summary measure, area under the curve (AUC) of CIPN20 motor neuropathy subscale as the endpoint. This AUC will be prorated by the number of chemotherapy cycles patients received.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.1","spread":"7.9"},{"groupId":"OG001","value":"93.3","spread":"8.0"},{"groupId":"OG002","value":"91.6","spread":"10.5"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Experiencing Grade 2+ and Grade 3+ Chronic Cumulative Neurotoxicity.","description":"Grades are determined by the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE version 4.0) and oxaliplatin-specific neurotoxicity scale, during and after chemotherapy. Higher grades symbolize greater severity of the adverse event.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.7","spread":null},{"groupId":"OG001","value":"44.8","spread":null},{"groupId":"OG002","value":"46.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.7","spread":null},{"groupId":"OG001","value":"7.8","spread":null},{"groupId":"OG002","value":"7.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Onset of Grade 2+ and Grade 3+ Chronic Cumulative Neurotoxicity and the Duration of the Chronic Cumulative Neurotoxicity During and After Chemotherapy","description":"Time to onset of grade 2+ and grade 3+ chronic cumulative neurotoxicity, the duration of the chronic cumulative neurotoxicity during and after the adjuvant oxaliplatin-based chemotherapy. Grades are determined by the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE version 4.0) and oxaliplatin-specific neurotoxicity scale, during and after chemotherapy. Higher grades symbolize greater severity of the adverse event.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"171","spread":null},{"groupId":"OG001","value":"173","spread":null},{"groupId":"OG002","value":"171","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"208","spread":null},{"groupId":"OG002","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Cumulative Oxaliplatin Doses That Can be Administered Without Dose-limiting Chronic Neurotoxicity","description":"A patient has a dose-limiting chronic neurotoxicity when they discontinue oxaliplatin-based chemotherapy because of neurotoxicity.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":"3"},{"groupId":"OG001","value":"8.4","spread":"2.5"},{"groupId":"OG002","value":"8.0","spread":"2.6"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Discontinuing Oxaliplatin-based Chemotherapy Because of Neurotoxicity","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.7","spread":null},{"groupId":"OG001","value":"27.7","spread":null},{"groupId":"OG002","value":"30.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With Acute Neuropathy Associated With Oxaliplatin","description":"This is the percent of patients who scored \\>=50 in all sequences of all cycles by arm for side effect Q1: Sensitivity to touching cold. This is a\\> repeated measurement of CIPN with possibly variable cycles for every patient. The CIPN subscale will be calculated by standard scoring algorithm and converted to 0-100 scale. Where 0 is no sensitivity and 100 is as bad as it can be.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"13","spread":null},{"groupId":"OG002","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"27","spread":null},{"groupId":"OG002","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"33","spread":null},{"groupId":"OG002","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"37","spread":null},{"groupId":"OG002","value":"36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"33","spread":null},{"groupId":"OG002","value":"39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"37","spread":null},{"groupId":"OG002","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"34","spread":null},{"groupId":"OG002","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"34","spread":null},{"groupId":"OG002","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"37","spread":null},{"groupId":"OG002","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"39","spread":null},{"groupId":"OG002","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"39","spread":null},{"groupId":"OG002","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"45","spread":null},{"groupId":"OG002","value":"32","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Calcium Gluconate and Magnesium Sulfate-induced Adverse Events as Measured by CTCAE Version 4.0","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"290","spread":null},{"groupId":"OG001","value":"259","spread":null},{"groupId":"OG002","value":"296","spread":null}]}]}]},{"type":"SECONDARY","title":"Area Under the Curve (AUC) of Patient-reported Quality of Life (QOL) as Measured by the Supplemental QOL Questionnaire","description":"This is a multivariate repeated measurement of CIPN with possibly variable cycles for every patient. The supplemental quality of life (QOL) subscale will be calculated by standard scoring algorithm and converted to 0-100 scale, where higher scores represent a higher quality of life. Rather than choosing the subscale at a fixed cycle of chemotherapy, we will adopt a summary measure, area under the curve (AUC) . This AUC will be prorated by the number of chemotherapy cycles patients received.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.7","spread":"15.5"},{"groupId":"OG001","value":"86.2","spread":"15.7"},{"groupId":"OG002","value":"84.5","spread":"16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.1","spread":"13.0"},{"groupId":"OG001","value":"88.8","spread":"13.4"},{"groupId":"OG002","value":"88.0","spread":"18.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.8","spread":"11.4"},{"groupId":"OG001","value":"90.6","spread":"12.6"},{"groupId":"OG002","value":"89.4","spread":"15.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.1","spread":"13.4"},{"groupId":"OG001","value":"88.5","spread":"14.4"},{"groupId":"OG002","value":"84.6","spread":"19.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.2","spread":"10.0"},{"groupId":"OG001","value":"87.6","spread":"13.8"},{"groupId":"OG002","value":"86.7","spread":"14.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.4","spread":"14.8"},{"groupId":"OG001","value":"81.8","spread":"15.7"},{"groupId":"OG002","value":"80.0","spread":"17.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.9","spread":"16.5"},{"groupId":"OG001","value":"76.5","spread":"17.3"},{"groupId":"OG002","value":"76.3","spread":"17.6"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":13,"n":117},"commonTop":["Nausea","Diarrhea","Vomiting","Neutrophil count decreased","White blood cell decreased"]}}}